Recombinant human thrombopoietin (rh-TPO) for the prevention of severe thrombocytopenia induced by high-dose cytarabine: a prospective, randomized, self-controlled study

References

• Reese ND, Schiller GJ. High-dose cytarabine (HD araC) in the treatment of leukemias: a review. Curr Hematol Malig Rep. 2013;8:141–148.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004;104:1624–1630.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Ponzoni M, Ferreri AJ, et al. Lymphoblastic lymphoma. Crit Rev Oncol Hematol. 2011;79:330–343.
   PubMed Web of Science ®Google Scholar
• Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: a retrospective analysis. Ann Oncol. 2011;22:1859–1864.
   PubMed Web of Science ®Google Scholar
• Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565–575.
   PubMed Web of Science ®Google Scholar
• Bergner N, Monsef I, Illerhaus G, et al. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Cochrane Database Syst Rev. 2012;11:CD009355.
   PubMedGoogle Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–4190.
   PubMed Web of Science ®Google Scholar
• Jalaeikhoo H, Yekaninejad MS, Hajizamani S, et al. Treatment of primary central nervous system lymphoma with high-dose methotrexate and radiotherapy in HIV-negative patients. Arch Iran Med. 2015;18:577–581.
   PubMed Web of Science ®Google Scholar
• Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer. 2003;98:1196–1205.
   PubMed Web of Science ®Google Scholar
• Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP–an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12:1169–1176.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015;29:282–294.
   PubMed Web of Science ®Google Scholar
• Liu Z, Li de C, Zhu YP. Interleukin-11-induced capillary leak syndrome companied with abdominal chylous leakage in primary sigmoid carcinoma patients with thrombocytopenia. J Can Res Ther. 2015;11:1024.
   Web of Science ®Google Scholar
• Wu S, Zhang Y, Xu L, et al. Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy. Support Care Cancer. 2012;20:1875–1884.
   PubMed Web of Science ®Google Scholar
• Kai-Feng W, Hong-Ming P, Hai-Zhou L, et al. Interleukin-11-induced capillary leak syndrome in primary hepatic carcinoma patients with thrombocytopenia. BMC Cancer. 2011;11:204.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med. 1997;126:673–681.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia. Semin Hematol. 2000;37:28–34.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S. Recombinant human thrombopoietin in myelosuppressive chemotherapy. Oncology (Williston Park). 2001;15:35–38.
   PubMedGoogle Scholar
• Tijssen MR, van der Schoot CE, Voermans C, et al. Clinical approaches involving thrombopoietin to shorten the period of thrombocytopenia after high-dose chemotherapy. Transfus Med Rev. 2006;20:283–293.
   PubMed Web of Science ®Google Scholar
• Bai CM, Xu GX, Zhao YQ, et al. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2004;26:437–441.
   PubMedGoogle Scholar
• Bai CM, Zou XY, Zhao YQ, et al. [The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia]. Zhonghua Yi Xue Zhi. 2004;84:397–400.
   PubMedGoogle Scholar
• Dai XF, Yu J, Liu L, et al. [Value of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor]. Zhonghua Zhong Liu Za Zhi. 2008;30:623–625.
   PubMedGoogle Scholar
• Xu YH, Chen ZW, Ye XY, et al. [Evaluation of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in lung cancer patients]. Zhonghua Zhong Liu Za Zhi. 2008;30:716–719.
   PubMedGoogle Scholar
• Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241–3248.
   PubMed Web of Science ®Google Scholar
• Parameswaran R, Lunning M, Mantha S, et al. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. 2014;22:1217–1222.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kanashima H, Nakao T, et al. Retrospective analysis of eltrombopag for the treatment of refractory primary immune thrombocytopenia in Japan. Rinsho Ketsueki. 2013;54:444–450.
   PubMedGoogle Scholar
• Kuter DJ. Milestones in understanding platelet production: a historical overview. Br J Haematol. 2014;165:248–258.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000;132:364–368.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Hamlin PA, Gabrilove J, et al. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol. 2007;18:1842–1850.
   PubMed Web of Science ®Google Scholar
• Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000;95:2530–2535.
   PubMed Web of Science ®Google Scholar
• Li Q, Ye M, Xiao W, et al. [Prophylactic recombinant human thrombopoietin treatment alleviates chemotherapy- induced thrombocytopenia in tumor patients]. Nan Fang Yi Ke Da Xue Xue Bao. 2012;32:1064–1066.
   PubMedGoogle Scholar
• Linker C. Thrombopoietin in the treatment of acute myeloid leukemia and in stem-cell transplantation. Semin Hematol. 2000;37:35–40.
   PubMed Web of Science ®Google Scholar
• Wu Y, Aravind S, Ranganathan G, et al. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000–2007. Clin Ther. 2009;31:2416–2432.
   PubMed Web of Science ®Google Scholar
• Lin TY. Phase II/III randomized trial of CID-ATT with radiotherapy compared with CHOP with radiotherapy as first-line treatment for previously untreated early staging extranodal NK/T-cell lymphoma, nasal type (ENKL). J Clin Oncol. 2013;31:8508.
   Google Scholar
• Vadhan-Raj S, Patel S, Bueso-Ramos C, et al. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol. 2003;21:3158–3167.
   PubMed Web of Science ®Google Scholar